Dr Giacchetti discusses the findings from a study of patient-selected timing of the daily oral intake of adjuvant hormone therapy and everolimus in breast cancer and how this study highlights the need for further research combining the fields of chronobiology and oncology.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Sylvie Giacchetti, MD, a breast medical oncologist at St. Louis Hospital in Paris, France. She joined us to discuss a study of patient-selected timing of the daily oral intake of adjuvant hormone therapy and everolimus (Afinitor) that was presented at the 2022 San Antonio Breast Cancer Symposium.
The phase 3 UCBG-UNIRAD trial (NCT01805271) showed that the addition of everolimus to adjuvant hormone therapy did not improve 3-year disease-free survival rates in patients with high-risk early breast cancer. This study, though negative, prompted Giacchetti and colleagues to compile the times of day that patients elected to take the study drugs, the first step in a larger research effort to determine whether the timing of intake affects the agents’ efficacy or safety.
In our exclusive interview, Dr Giacchetti discussed the findings from this analysis of patient characteristics, the importance of considering circadian rhythms when recommending the times of day patients should receive certain agents, and how this analysis highlights the need for further research combining the fields of chronobiology and oncology.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.